PPD

PPD is described on its official site as the PPD clinical research business of Thermo Fisher Scientific, a leading global provider of contract research organization (CRO) solutions. It began in 1985 as a one-person consulting firm founded by Fred Eshelman, Pharm. D., and states that it has conducted clinical trials in more than 100 countries. Its offerings include therapeutic expertise across more than 20 therapeutic areas, end-to-end solutions, laboratory services, functional partnership service (FSP) solutions, biotech solutions, and drug development digital solutions.

PPD began in 1985 as a one-person consulting firm founded by Fred Eshelman, Pharm. D. In 1986 it expanded its scope to include development services, and in 1989 it incorporated in North Carolina. In 1995 it expanded to Europe, the Middle East and Africa with the acquisition of Gabbay Group, a CRO in the U.K. In 1996 it had its initial public stock offering, acquired Applied BioScience International (which includes Pharmaco and several European regional drug development companies), and expanded to Latin America with the acquisition of a Brazil-based CRO. In 1997 it began offering drug discovery services and expanded to the Asia-Pacific region with the opening of an office in Australia. In 2001 it declared a one-for-one stock dividend and expanded to the Asia-Pacific region with the opening of an office in Australia. In 2002 it acquired Medical Research Laboratories International, adding central lab services in North America, Europe, the Middle East and Africa, and acquired ProPharma, an Asian-based CRO, which significantly expanded PPD's footprint in Asia-Pacific. The PPD clinical research business of Thermo Fisher Scientific has conducted clinical trials in more than 100 countries.

A leading provider of global clinical research solutions and CRO solutions.

• 2021.04.15

  Reported2021.04.15

  Medable announces $78 million in funding[5]Medable宣布获得7800万美元融资biospace.com

  Medable announced $78 million in new funding, led by Sapphire Ventures, with participation from Obvious Ventures and follow-on investment from existing investors.

• Unconfirmed

  PPD and Lupus Therapeutics collaborate on lupus clinical research[6]PPD与Lupus Therapeutics合作开展狼疮临床研究wilmingtonbiz.com

  PPD and Lupus Therapeutics are collaborating on lupus clinical research. The collaboration is intended to expand and enhance research for PPD’s pharmaceutical and biotech customers, and the article describes access to Lupus Clinical Investigators Network research sites and investigators.

• Unconfirmed

  PPD begins trading on Nasdaq[7]PPD 开始在纳斯达克交易wilmingtonbiz.com

  PPD began trading on the Nasdaq Global Select Market under the symbol PPD, returning to public-company status. Its shares opened at $31 per share.

• 2020.01.11

  Reported2020.01.11

  Bitty & Beau’s Coffee opens location at PPD[8]Bitty & Beau’s Coffee 在 PPD 开设门店wect.com

  PPD and Bitty & Beau’s Coffee partnered to establish a Bitty & Beau’s location within PPD, with the stated aim of providing more opportunities for workers with disabilities and promoting inclusion.

• 2020.01.09

  PPD files for IPO[9]PPD提交首次公开募股申请wilmingtonbiz.com

  PPD filed with the SEC for an initial public offering to raise up to $100 million.

Read more

1. 1Global Pharmaceutical Contract Research Organization (CRO) | PPDppd.com
2. 2Our History | PPDppd.com
3. 3Company Resources | PPDppd.com
4. 4Corporate Responsibility | PPDppd.com
5. 5Medable宣布获得7800万美元融资biospace.com
6. 6PPD与Lupus Therapeutics合作开展狼疮临床研究wilmingtonbiz.com
7. 7PPD 开始在纳斯达克交易wilmingtonbiz.com
8. 8Bitty & Beau’s Coffee 在 PPD 开设门店wect.com
9. 9PPD提交首次公开募股申请wilmingtonbiz.com
10. 10PPD launches its initial public offering of 60 million shareswect.com